



**Recommendation to the Cancer Systemic Therapy Policy
Committee (CSTPC) from Capital District Health
Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Sorafenib in Advanced Hepatocellular
Carcinoma (HCC)**

Approved Use of Sorafenib:

Sorafenib is a **single agent first line systemic therapy** option in adult patients with a diagnosis of HCC not candidates for curative intent treatments (transplantation, hepatic resection), or other well established palliative interventions (ablation, transcatheter arterial chemo-embolization (TACE), internal radiation).

Patients:

Candidates for sorafenib are patients affected by HCC with Child-Pugh Class A liver dysfunction (mild hepatic impairment) and ECOG performance status 0-1. This patient population may have either progression of disease or are not suitable candidates for curative interventions (hepatic resection) or other palliative therapies (ablation, TACE, internal radiation).

- This policy recommendation represents a **new guideline document** and a restriction of sorafenib to include advanced HCC patients as first-line systemic therapy option.